Alex Zisson | Managing Director, H.I.G. Capital

Alex_ZissonAlex is the Managing Director of H.I.G. Capital. Before that, he was a partner at Thomas, McNerney & Partners since its first fund was raised in 2002 until 2016.  He currently serves on the board of directors for Auspex Pharmaceuticals, Clarus Therapeutics, and InnoPharma.  Alex is a member of the Industry Advisory Board of the Children’s Tumor Foundation, and a board member of Advanced Medical Research Institute of Canada Development Corporation (AMRIC-DC), which is focused on economic development in northern Ontario.  He is also an advisor for the Partnership Fund of NYC, which manages a bioaccelarator to advance local healthcare research and is on the Life Sciences Council for Springboard Enterprises, a group that assists female entrepreneurs.

Prior to Thomas, McNerney, Alex spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan).  During his tenure at H&Q, Alex led research teams covering the biotechnology, specialty pharmaceuticals, large-cap pharmaceuticals, drug delivery and diagnostics industries.  After the merger of Chase H&Q and JPMorgan, Alex also became the firm’s healthcare strategist. He was named twice in The Wall Street Journal All-Star Analysts Survey, including his last year at JPMorgan in which he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and ‘home run’ hitting (#8 across all industries).

He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.